6. January 2012 15:14
EpiCept Corporation has appointed US pharmaceutical veteran Dr Alan Dunton to its Board of Directors and named him Non-Executive Chairman.
Dr Dunton replaces Bob Savage – who will remain as a director – with immediate effect after serving in a number of senior positions within the industry.
Jack Talley, EpiCept’s President and CEO, called Dr Dunton a “seasoned pharmaceutical executive” and said the company was delighted to have attracted him to the role.
The founder of Danerius, LLC, Dr Dunton is currently a director at Targacept, Inc., Palatin Technologies and Oragenics, Inc. Previously he served as President and CEO of Panacos Pharmaceuticals between 2007 and 2009 and served Metaphore Pharmaceuticals in a similar role from 2003 to 2005.
Prior to that he was a Senior Executive within the Pharmaceuticals Group of Johnson & Johnson, during which time he was the President of The Janssen Research Foundation where he was responsible for the development and regulatory activities for Levaquin, Topamax and Risperdal.
Mr Tally added: “Given the recent success with the FDA regarding the future of AmiKet in neuropathic pain, the Board believes that his business leadership and deep experience in clinical development and regulatory issues makes him highly qualified to lead the Board in its oversight and governance as EpiCept seeks to create the greatest possible shareholder value leveraging its product portfolio.”